Lilly heads into Q1 earnings with GLP-1 drugs driving growth. However, pricing pressure, rising costs, and softer Foundayo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results